Sevelamer 800 mg is a medication used to control serum phosphorus levels in adult patients with chronic kidney disease (CKD) on hemodialysis [1]. It is also indicated for adult patients with CKD not on dialysis but with serum phosphorus of 6.5 mg/dL or greater, who cannot be adequately managed with phosphate binders intended for oral use [1].
How does Sevelamer 800 mg work?
Sevelamer 800 mg is an independent binder that works in the gastrointestinal tract. It binds to phosphate from the diet, preventing it from being absorbed into the bloodstream [1]. This helps to lower elevated serum phosphorus levels, a common complication in patients with kidney disease.
What is the recommended dosage for Sevelamer 800 mg?
The starting dose of Sevelamer 800 mg for patients with CKD on hemodialysis is typically 1600 mg or 2400 mg per day, divided into three doses per day [1]. Doses can be increased based on serum phosphorus levels. For patients with CKD not on dialysis, the starting dose is usually 800 mg three times a day [1]. Dosage adjustments are made to achieve and maintain a target serum phosphorus level of 5.5 mg/dL or less [1].
When does Sevelamer 800 mg patent expire?
Information regarding the specific patent expiry dates for Sevelamer 800 mg can be found on specialized pharmaceutical patent tracking websites. DrugPatentWatch.com provides comprehensive data on drug patents and their expiration timelines [2].
Can generic versions of Sevelamer 800 mg be available?
The availability of generic versions of Sevelamer 800 mg depends on patent expiry and regulatory approvals. Once patents expire and generic manufacturers receive approval from regulatory bodies like the FDA, generic alternatives can enter the market [2].
What are the potential side effects of Sevelamer 800 mg?
Commonly reported side effects of Sevelamer 800 mg include nausea, vomiting, diarrhea, constipation, and abdominal pain [1]. Less common side effects may include rash, itching, and hypersensitivity reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How does Sevelamer 800 mg compare to other phosphate binders?
Sevelamer 800 mg is a non-calcium, non-aluminum-based phosphate binder [1]. Other phosphate binders include calcium-based binders (like calcium acetate and calcium carbonate) and aluminum-based binders [3]. Sevelamer is often preferred as it does not contribute to calcium or aluminum accumulation, which can be problematic in patients with kidney disease [3]. It is also available in hydrochloride and carbonate formulations, with Sevelamer carbonate being more effective at reducing serum bicarbonate levels [1].
What clinical data supports the use of Sevelamer 800 mg?
Clinical trials have demonstrated Sevelamer 800 mg's efficacy in reducing serum phosphorus levels in patients with CKD [1]. Studies have shown significant reductions in phosphorus, as well as reductions in LDL cholesterol and total cholesterol, and increases in HDL cholesterol [1].
What are the risks associated with Sevelamer 800 mg?
Potential risks include gastrointestinal disturbances, as mentioned previously [1]. In rare cases, intestinal obstruction, impaction, and perforation have been reported [1]. Patients with a history of bowel obstruction should use Sevelamer with caution [1]. It is also important to note that Sevelamer can affect the absorption of other medications, so it is recommended to take other drugs at least one hour before or three hours after Sevelamer [1].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.kidney.org/atoz/content/phosphate-binders